2017 国际共识会议报告:成人T细胞白血病-淋巴瘤

2019-01-18 国外血液科相关专家小组 J Clin Oncol. 2019 Jan 18.

成人T细胞白血病淋巴瘤(ATL)是一种难治性成熟T细胞恶性肿瘤,临床表现多样。在2017年第18届国际人类逆转录病毒学-人类亲T细胞病毒(HTLV)及其相关病毒会议在日本东京召开,主要对2009年共识报告进行了更新。

中文标题:

2017 国际共识会议报告:成人T细胞白血病-淋巴瘤

英文标题:

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

发布日期:

2019-01-18

简要介绍:

成人T细胞白血病淋巴瘤(ATL)是一种难治性成熟T细胞恶性肿瘤,临床表现多样。在2017年第18届国际人类逆转录病毒学-人类亲T细胞病毒(HTLV)及其相关病毒会议在日本东京召开,主要对2009年共识报告进行了更新。 

拓展指南:淋巴瘤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 国际共识会议报告:成人T细胞白血病-淋巴瘤)] GetToolGuiderByIdResponse(projectId=1, id=c5fb71c0016936b0, title=2017 国际共识会议报告:成人T细胞白血病-淋巴瘤, enTitle=Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report., guiderFrom=J Clin Oncol. 2019 Jan 18., authorId=null, author=, summary=成人T细胞白血病淋巴瘤(ATL)是一种难治性成熟T细胞恶性肿瘤,临床表现多样。在2017年第18届国际人类逆转录病毒学-人类亲T细胞病毒(HTLV)及其相关病毒会议在日本东京召开,主要对2009年共识报告进行了更新。 , cover=, journalId=null, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jan 18 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>成人T细胞白血病淋巴瘤(ATL)是一种难治性成熟T细胞恶性肿瘤,临床表现多样。在2017年第18届国际人类逆转录病毒学-人类亲T细胞病毒(HTLV)及其相关病毒会议在日本东京召开,主要对2009年共识报告进行了更新。 </div> <div><br> </div>拓展指南:<strong>与<font color="red">淋巴瘤</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=4439e1c001682573" title="NCCN临床实践指南:T细胞淋巴瘤(2019.V2)" target="_blank">NCCN临床实践指南:T细胞淋巴瘤(2019.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6e1391c001680687" title="淋巴瘤诊疗规范(2018年版)" target="_blank">淋巴瘤诊疗规范(2018年版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e35fe1c0016e9377" title="2018 BAD指南:原发性皮肤淋巴瘤的管理" target="_blank">2018 BAD指南:原发性皮肤淋巴瘤的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6dbdc1c0016e36b1" title="NCCN临床实践指南:B细胞淋巴瘤(2019.V1)" target="_blank">NCCN临床实践指南:B细胞淋巴瘤(2019.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e02631c0016e10f6" title="NCCN临床实践指南:T细胞淋巴瘤(2019.V1)" target="_blank">NCCN临床实践指南:T细胞淋巴瘤(2019.V1)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%B7%8B%E5%B7%B4%E7%98%A4" target="_blank">有关淋巴瘤更多指南</a></ul>, tagList=[TagDto(tagId=86048, tagName=成人T细胞白血病-淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6842, appHits=91, showAppHits=0, pcHits=5479, showPcHits=3198, likes=153, shares=0, comments=2, approvalStatus=1, publishedTime=Mon Jan 28 19:39:00 CST 2019, publishedTimeString=2019-01-18, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 28 19:39:00 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:33:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 国际共识会议报告:成人T细胞白血病-淋巴瘤)])
2017 国际共识会议报告:成人T细胞白血病-淋巴瘤
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1217519, encodeId=979b121e5192a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat May 07 08:08:09 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966424, encodeId=cf1e966424d2, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=367a2260608, createdName=12182b71m12暂无昵称, createdTime=Mon May 17 22:49:30 CST 2021, time=2021-05-17, status=1, ipAttribution=)]
    2022-05-07 charly

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1217519, encodeId=979b121e5192a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat May 07 08:08:09 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966424, encodeId=cf1e966424d2, content=好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=367a2260608, createdName=12182b71m12暂无昵称, createdTime=Mon May 17 22:49:30 CST 2021, time=2021-05-17, status=1, ipAttribution=)]
    2021-05-17 12182b71m12暂无昵称

    好!

    0